Targeted therapies for APDS focus on inhibiting the PI3K-AKT-mTOR pathway, with mTOR inhibitors (e.g., rapamycin/sirolimus) and selective PI3Kδ inhibitors (e.g., idelalisib or duvelisib) being the primary options, Recent studies have highlighted the potential curative role of allo-HSCT in APDS. This evidence concerns the gene MTOR and activated PI3K-delta syndrome.